Artificial intelligence supporting cancer patients across Europe-The ASCAPE project

Lazaros Tzelves, Ioannis Manolitsis, Ioannis Varkarakis, Mirjana Ivanovic, Miltiadis Kokkonidis, Cristina Sabater Useros, Thanos Kosmidis, Montserrat Muñoz, Imma Grau, Manos Athanatos, Anamaria Vizitiu, Konstantinos Lampropoulos, Tzortzia Koutsouri, Dimitra Stefanatou, Konstantinos Perrakis, Christina Stratigaki, Serge Autexier, Paris Kosmidis, Antonis Valachis, Lazaros Tzelves, Ioannis Manolitsis, Ioannis Varkarakis, Mirjana Ivanovic, Miltiadis Kokkonidis, Cristina Sabater Useros, Thanos Kosmidis, Montserrat Muñoz, Imma Grau, Manos Athanatos, Anamaria Vizitiu, Konstantinos Lampropoulos, Tzortzia Koutsouri, Dimitra Stefanatou, Konstantinos Perrakis, Christina Stratigaki, Serge Autexier, Paris Kosmidis, Antonis Valachis

Abstract

Introduction: Breast and prostate cancer survivors can experience impaired quality of life (QoL) in several QoL domains. The current strategy to support cancer survivors with impaired QoL is suboptimal, leading to unmet patient needs. ASCAPE aims to provide personalized- and artificial intelligence (AI)-based predictions for QoL issues in breast- and prostate cancer patients as well as to suggest potential interventions to their physicians to offer a more modern and holistic approach on cancer rehabilitation.

Methods and analyses: An AI-based platform aiming to predict QoL issues and suggest appropriate interventions to clinicians will be built based on patient data gathered through medical records, questionnaires, apps, and wearables. This platform will be prospectively evaluated through a longitudinal study where breast and prostate cancer survivors from four different study sites across the Europe will be enrolled. The evaluation of the AI-based follow-up strategy through the ASCAPE platform will be based on patients' experience, engagement, and potential improvement in QoL during the study as well as on clinicians' view on how ASCAPE platform impacts their clinical practice and doctor-patient relationship, and their experience in using the platform.

Ethics and dissemination: ASCAPE is the first research project that will prospectively investigate an AI-based approach for an individualized follow-up strategy for patients with breast- or prostate cancer focusing on patients' QoL issues. ASCAPE represents a paradigm shift both in terms of a more individualized approach for follow-up based on QoL issues, which is an unmet need for cancer survivors, and in terms of how to use Big Data in cancer care through democratizing the knowledge and the access to AI and Big Data related innovations.

Trial registration: Trial Registration on clinicaltrials.gov: NCT04879563.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Generic flowchart of study procedures…
Fig 1. Generic flowchart of study procedures corresponding to ASCAPE-based follow-up strategy.

References

    1. Miller KD, Nogueira L, Mariotto AB, et al.. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–385. doi: 10.3322/caac.21565
    1. Nardin S, Mora E, Varughese FM, et al.. Breast Cancer Survivorship, Quality of Life, and Late Toxicities. Front Oncol. 2020;10:864. doi: 10.3389/fonc.2020.00864
    1. Sanda MG, Dunn RL, Michalski J, et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61. doi: 10.1056/NEJMoa074311
    1. Shakeel S, Tung J, Rahal R, Finley C. Evaluation of Factors Associated With Unmet Needs in Adult Cancer Survivors in Canada. JAMA Netw Open. 2020;3:e200506. doi: 10.1001/jamanetworkopen.2020.0506
    1. Brédart A, Kop JL, Griesser AC, et al.. Assessment of needs, health-related quality of life, and satisfaction with care in breast cancer patients to better target supportive care. Ann Oncol. 2013;24:2151–8. doi: 10.1093/annonc/mdt128
    1. Paterson C, Robertson A, Smith A, Nabi G. Identifying the unmet supportive care needs of men living with and beyond prostate cancer: A systematic review. Eur J Oncol Nurs. 2015;19:405–18. doi: 10.1016/j.ejon.2014.12.007
    1. Watson E, Shinkins B, Frith E, et al.. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int. 2016;117:E10–9. doi: 10.1111/bju.13122
    1. Hazarika I. Artificial intelligence: opportunities and implications for the health workforce. Int Health. 2020;12:241–245. doi: 10.1093/inthealth/ihaa007
    1. Nagy M, Radakovich N, Nazha A. Machine Learning in Oncology: What Should Clinicians Know? JCO Clin Cancer Inform. 2020. Sep;4:799–810. doi: 10.1200/CCI.20.00049
    1. BREAST-Q, “Qportfolio,” 2006. [Online]. Available at: . (Accessed: February 1, 2021).
    1. EORTC Quality of Life [Online]. Available at: (Accessed: February 1, 2021).
    1. EORTC Quality of Life [Online]. Available: (Accessed: February 1, 2021).
    1. ePROVIDE [Online]. Available at: (Accessed: Februari 1, 2021).
    1. The DASH Outcome Measure [Online]. Available at: (Accessed: February 1, 2021).
    1. EORTC Quality of Life [Online]. Available at: (Accessed: February 1, 2021).
    1. Rosen R, Riley A, Wagner G, et al.. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–830. doi: 10.1016/s0090-4295(97)00238-0
    1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x
    1. Harrington S, Miale S, Edaugh D. Breast Cancer EDGE Task Force Outcomes: Clinical Measures of Health Related Quality of Life. Rehabilitation Oncology. 2015;33:5–17.
    1. Perdomo M, Davies C, Levenhagen K, Ryans K. BREAST CANCER EDGE TASK FORCE OUTCOMES: Assessment Measures of Secondary Lymphedema in Breast Cancer Survivors. Rehabilitation Oncology. 2014;32:22–35.
    1. Alappattu M, Harrington SE, Hill A, Roscow A, Jeffrey A. Oncology Section EDGE Task Force on Cancer: A systematic review of patient-reported measures for sexual dysfunction. Rehabil Oncol. 2017;35:137–143.
    1. Harrington S, Lee J, Colon G, Alappattu M. Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. Rehabil Oncol. 2016;34:27–35.
    1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:1194–1220. doi: 10.1093/annonc/mdz173
    1. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S; ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–1134. doi: 10.1016/j.annonc.2020.06.011
    1. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71:618–629. doi: 10.1016/j.eururo.2016.08.003
    1. Lozano-Rubí R, Muñoz Carrero A, Serrano Bazalote P, Pastor X. OntoCR: A CEN/ISO-13606 clinical repository based on ontologies. Journal of Biomedical Informatics 2016; 60:224–233. doi: 10.1016/j.jbi.2016.02.007

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir